TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage immuno-oncology and RNA therapeutics company, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018 and also as a director, will continue to provide transition services to ensure a smooth handover. The company has appointed John Tattory as interim CFO, also effective immediately.
Tattory brings over 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His background includes leadership positions at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies.
The leadership change comes at a critical time for TransCode Therapeutics as it advances its pipeline of novel cancer treatments. The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. Additionally, TransCode is developing a portfolio of first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells.
Fitzgerald's retirement marks the end of a tenure that spanned nearly five years, during which he helped guide the company through its initial public offering and early clinical development. His continued transition services should help maintain financial continuity as Tattory assumes the interim role. Tattory's extensive experience in life sciences finance, particularly with both large pharmaceutical firms and emerging biotechs, positions him to support TransCode's strategic and financial objectives.
The appointment of an interim CFO may signal that the company is conducting a search for a permanent replacement. Investors will likely watch closely to see how Tattory's expertise influences TransCode's financial strategy, especially given the capital-intensive nature of oncology drug development. The company's ability to secure funding and manage resources efficiently will be crucial as it progresses TTX-MC138 and other candidates through clinical trials.
For more details, the full press release can be accessed at https://nnw.fm/8G3ik. Updates on TransCode Therapeutics are available in the company's newsroom at https://nnw.fm/RNAZ.
